Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease

Although new pharmaceutical therapy options have recently become available, hydroxyurea is still the most commonly used and affordable treatment option for sickle cell disease (SCD). This study aimed to update the evidence on hydroxyurea adherence and its association with clinical and economic outcomes among individuals with SCD. This retrospective study used Texas Medicaid claims data from 09/2011-08/2016. Individuals were included if they had >= 1 inpatient or >= 2 outpatient SCD diagnoses, had >= 1 hydroxyurea prescription, were 2-63years of age, and were continuously enrolled in Texas Medicaid between 6months before and 1year after the first hydroxyurea prescription fill date (index date). Hydroxyurea adherence (Medication Possession Ratio; MPR), vaso-occlusive crisis (VOC)-related outcomes, healthcare utilization and expenditures (SCD-related and all-cause) during the 1year following the index date were measured. Bivariate and multivariable analyses were used to address the study objectives. Among 1035 included individuals (age: 18.8 +/- 12.5years, female: 52.1%), 20.9% were adherent to hydroxyurea (defined as MPR >= 0.8). After adjustment for demographic and clinical characteristics, compared to being non-adherent, adhering to hydroxyurea was significantly associated with: a lower risk (Odds Ratio [OR] = 0.480, p =.0007) and hazard rate (Hazard Ratio [HR] = 0.748, p =.0005) of a VOC event, fewer VOC events (Incidence Rate Ratio [IRR] = 0.767, p =.0009), fewer VOC-related hospital days (IRR = 0.593, p =.0003), fewer all-cause and SCD-related hospitalizations (IRR = 0.712, p =.0008; IRR = 0.707, p =.0008, respectively) and emergency department visits (IRR = 0.768, p =.0037; IRR = 0.746, p =.0041, respectively), and lower SCD-related total healthcare expenditures (IRR = 0.796, p =.0266). Efforts to increase adherence to hydroxyurea could improve clinical and economic outcomes among individuals with SCD.